Enliven Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $83,529,000.
Profit Margin
| 2017 | 0 | 0 | |
|---|---|---|---|
| 2018 | 0 | -11.33M | |
| 2019 | 0 | -23.46M | |
| 2020 | 0 | -18.93M | |
| 2021 | 0 | -24.71M | |
| 2022 | 0 | -37.75M | |
| 2023 | 0 | -71.58M |
ELVN Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 297K | 622K | 99K | 97K | 33K | 0 | 0 |
Gross profit | -297K | -622K | -99K | -97K | -33K | 0 | 0 |
Operating exp. | |||||||
Research and development | 64.57M | 31.02M | 20.47M | 8.24M | 19.00M | 8.23M | 7.91M |
Selling and marketing | 0 | 0 | 0 | 0 | -33K | 0 | 0 |
Total operating expenses | 83.52M | 38.79M | 24.76M | 9.31M | 24.08M | 10.67M | 8.90M |
Operating income | -83.52M | -38.79M | -24.76M | -9.31M | -24.11M | -10.67M | -8.90M |
Other income (expenses), net | 11.94M | 1.12M | 22K | -9.64M | 653K | -660K | 9.12M |
Income before tax | -71.58M | -37.66M | -24.74M | -18.96M | -23.46M | -11.33M | 221K |
Income tax expense | 0 | 88K | -22K | -31K | 653K | 0 | 221K |
Net income | -71.58M | -37.75M | -24.71M | -18.93M | -23.46M | -11.33M | 0 |
Earnings per share | |||||||
Basic EPS | -2.01 | -12.08 | -10.72 | -14.13 | -5.43 | -1.2 | 0 |
Diluted EPS | -2.01 | -12.08 | -10.72 | -14.13 | -5.43 | -1.2 | 0 |
| Data source | Data source |